Dr. Djaballah has several years of industrial experience in early drug discovery gained over the years in pharma and biotech companies. He has extensive experiences in the areas of fluorescence technology, assay development, automation/robotics, HTS, compound & screening data management, software development & novel technologies. Dr Djaballah has been involved in developing and screening several targets in various therapeutic areas, including antibacterials, antivirals, antifungals, diabetes, CNS, cardiovascular, oncology & inflammation. He is currently the director of the high throughput drug screening core facility at Memorial Sloan Kettering Cancer Centre in New York. He obtained his BSc (Hons.) in biochemistry and biotechnology from the University of Birmingham, and his PhD in biochemistry from the University of Leicester, both in England.
Comparative Analysis of RNAi Screening Technologies at Genome-scale
We utilized the two most popular RNAi technologies (siRNA duplex and shRNA hairpin) in order to perform a head to head comparison of both performance and hit nomination output. Using a previously developed EGFP-based high content biosensor cell based assay, we first executed on an siRNA screen against the Ambion Silencer Select V4.0 library nominating 1,273 candidates, followed by a second shRNA screen against the TRC1 library nominating 497 candidates. I will present our findings and discuss some likely reasons for the observed differential outcomes.
Add to Calendar ▼2014-04-29 00:00:002014-04-30 00:00:00Europe/LondonGenomics Research 2014Genomics Research 2014 in South San Francisco, CA, USASouth San Francisco, CA, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com
